Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)
- Posted
- April 12, 2022
- Closed
- May 23, 2025
- Cost sharing
- No
- Instrument
- Grant
- Assistance listing
- 93.393
- Archives
- June 22, 2025
Program funding history
Awards made under Assistance Listing 93.393 across FY2025–FY2027, from public federal spending records.
- FY2025 obligated
- $803.1M
- FY2026 obligated
- $769.4M
- FY2027 (to date) obligated
- $0
- Awards in window
- 2,546
Top recipients: The Univeristy of Texas M.d. Anderson Cancer Center, Dana-farber Cancer Institute, Inc., Sloan-kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York, University of North Carolina at Chapel Hill
Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →
Synopsis
This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information and/or meta data obtained from platforms including but not limited to lower resolution diagnostic acquisitions and systemic biomarker results to high resolution single-cell analytics / imaging applied to the characterization of heterogeneous cell populations within tumor for improving current approaches for: (1) the early detection of organ confined premetastatic aggressive cancer, and, (2) identifying precancerous lesions associated with a subsequent lethal phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions by improving detection sensitivity and specificity of integrated multiparametric platforms. For example, N-dimensional co-registered, cross-correlated imaging data integrated with multiplexed biomarker results and/or digital pathomics or glycomic, or metabolomic imaging using analytic strategies such as artificial intelligence or virtual reality visualization techniques. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of potentially lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.
Who can apply
- Native American tribal governments (Federally recognized)
- Special district governments
- Independent school districts
- Small businesses
- City or township governments
- State governments
- Private institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- For profit organizations other than small businesses
- Public and State controlled institutions of higher education
- County governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Native American tribal organizations (other than Federally recognized tribal governments)
- Public housing authorities/Indian housing authorities
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
The official record
Grants.gov published the official terms and dates of this opportunity; this page keeps them as they were listed.
View on Grants.gov Full announcement
New to federal funding? How to read an announcement · Who can apply · How grants work
Tell me when this program posts again
This round has closed. One email the morning after this program is posted again under a new number (we watch for about two years), and one more about a week before that round closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.
Similar grants
- Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)
- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
- Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
- Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)
Same-day alerts, matched to you
The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.
Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.
See pricing